Evidence map›Paper›PMID 29868618›Full record

ArticleFrontiers in veterinary science2018

Immunosignature Differentiation of Non-Infectious Meningoencephalomyelitis and Intracranial Neoplasia in Dogs.

Bathilda B Lake, John Henry Rossmeisl, Julie Cecere, Phillip Stafford, Kurt L Zimmerman

Open access · goldAbstract read
In one paragraph

Article in Frontiers in veterinary science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Bathilda B LakeDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, United States.
John Henry RossmeislDepartment of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, United States.
Julie CecereDepartment of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, United States.
Phillip StaffordBiodesign Institute, Center for Innovations in Medicine, Arizona State University, Tempe, AZ, United States.
Kurt L ZimmermanDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, United States.
Virginia–Maryland College of Veterinary Medicine · USArizona State University · US

Funding

Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBMP01CA207206 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DEBINSKI, WALDEMAR · 2017 to 2021
$9.0M
Molecular Combinatorial Therapy of Glioblastoma MultiformeR01CA139099 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DEBINSKI, WALDEMAR · 2010 to 2014
$1.5M
NCI NIH HHS P01 CA207206NCI NIH HHS R01 CA139099
6 · The paper itself

Abstract

A variety of inflammatory conditions of unknown cause (meningoencephalomyelitis of unknown etiology-MUE) and neoplastic diseases can affect the central nervous system (CNS) of dogs. MUE can mimic intracranial neoplasia both clinically, radiologically and even in some cases, histologically. Serum immunosignature protein microarray assays have been used in humans to identify CNS diseases such as Alzheimer's and neoplasia, and in dogs, to detect lymphoma and its progression. This study evaluated the effectiveness of immunosignature profiles for distinguishing between three cohorts of dogs: healthy, intracranial neoplasia, and MUE. Using the learned peptide patterns for these three cohorts, classification prediction was evaluated for the same groups using a 10-fold cross validation methodology. Accuracy for classification was 100%, as well as 100% specific and 100% sensitive. This pilot study demonstrates that immunosignature profiles may help serve as a minimally invasive tool to distinguish between MUE and intracranial neoplasia in dogs.

Indexed as

canineimmunosignatureintracranial neoplasiameningoencephalomyelitis of unknown etiologypeptide microarray

Identifiers

PMID29868618
PMCPMC5958519
OpenAlexW2802631605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.